相关实验视频

Updated: Jun 27, 2025

Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock

Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock

Published on: May 19, 2022

兰诺在慢性全封闭性皮肤冠状动脉干预中使用

Michaella Alexandrou¹, Deniz Mutlu¹, Athanasios Rempakos¹

¹Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

The Journal of invasive cardiology

|May 1, 2024

概括

在慢性全闭性皮肤冠状动脉干预 (CTO-PCI) 患者中使用兰诺与更复杂的手术和更高的重大心脏不良事件 (MACE) 有关. 这表明,罗纳可能表明接受CTO-PCI的高风险患者.

科学领域:

心脏病学心脏病学
干预心脏病学干预心脏病学
药理学药理学是指药理学的学科.

背景情况:

兰诺是一种治疗慢性心痛和持续症状的抗心痛药物.
慢性全封闭 (CTO) 穿皮冠状动脉干预 (PCI) 是一个复杂的程序.
了解影响CTO-PCI结果的患者因素至关重要.

研究的目的:

调查基线 ranolazine 使用对 CTO-PCI.结果的影响.
分析罗纳拉与手术成功以及主要心脏不良事件 (MACE) 之间的关联.

主要方法:

从PROGRESS-CTO注册表 (2012-2023) 中分析了11,491个CTO-PCI程序.
患者特征,病变复杂性和Ranolazine用户与非用户之间的结果的比较.
多变量分析以调整混因素.

主要成果:

接受罗纳拉的患者有更多的并发症和复杂的病变.
在 ranolazine 用户中观察到较低的程序和技术成功率 (无变量分析).
在Ranolazine使用者中发现MACE的发病率更高 (单变量和多变量分析).

结论:

在CTO-PCI患者的基线罗纳拉使用与MACE的增加有关.
兰诺可以作为复杂PCI的高风险患者的标志物.
需要进一步的研究来澄清 ranolazine 对 CTO-PCI 结果的独立影响.

关键词:

在CTO-PCI中.慢性完全封闭症慢性完全封闭症冠状动脉疾病是一种冠状动脉疾病.通过皮肤进行冠状动脉干预.对于 ranolazine 的使用情况.

更多相关视频

Author Spotlight: A Novel Standardized Technique for Real-Time Biomedical Imaging of Acute Myocardial Injury

Author Spotlight: A Novel Standardized Technique for Real-Time Biomedical Imaging of Acute Myocardial Injury

Published on: March 22, 2024

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

相关概念视频

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...